Navigation Links
Amira Announces AM103 and AM803 Patent Grant in the United Kingdom
Date:7/13/2010

SAN DIEGO, July 13 /PRNewswire/ -- Amira Pharmaceuticals, Inc. today announced that the U.K. Intellectual Property Office has granted patent number GB2431927, titled, "5-Lipoxygenase Activating Protein (FLAP) Inhibitors," which includes coverage of Amira's AM103 and AM803 FLAP inhibitors for the treatment of respiratory disorders.

In January 2008, Amira and GlaxoSmithKline (GSK) entered into a worldwide exclusive agreement allowing GSK to develop, manufacture and commercialize specified FLAP inhibitors for the treatment of respiratory and cardiovascular disease.  AM803 was added to the license agreement later in 2008.  GSK is currently conducting Phase 2 clinical trials in respiratory disorders with an Amira-licensed FLAP inhibitor.

"Amira continues to be successful in obtaining patent coverage for compounds being advanced in clinical trials," said John Hutchinson, Ph.D., Vice President of Chemistry.  "This patent covering both AM103 and AM803 is the third issued this year, following two patents related to our DP2 receptor antagonists granted by the United Kingdom."  Bob Baltera, Chief Executive Officer of Amira, added, "This patent relates to some of the first compounds developed by Amira.  It reflects our ongoing objective to secure strong patent protection around each of our development programs."

The newly granted claims cover novel inhibitors of the FLAP protein.  The patent also discloses uses of FLAP inhibitors for the treatment of inflammatory diseases such as asthma, cardiovascular disease, dermatological disorders and ocular diseases.

About Amira

Founded in 2005 and headquartered in San Diego, Amira Pharmaceuticals is a small molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory disease.  Our discovery team is building on unparalleled insights into bioactive lipid pathways and complex signaling processes controlling many conditions including asthma, chronic obstructive pulmonary disease, cardiovascular and fibrotic diseases.  Amira has a partnership with GlaxoSmithKline for the development of FLAP (5-lipoxygenase activating protein) inhibitors in respiratory and cardiovascular disease.

Amira combines the rigor of a big pharmaceutical company with the ingenuity and energy of a small company, creating an environment for efficient development of novel compounds and effective pre-clinical and clinical program decisions.  Its scientific founders have successfully worked together for more than a decade and were pivotal in the discovery of a number of inflammatory drugs, including Singulair®.  The drug hunters at Amira are now actively leveraging their history of success to create high-value compounds for the future.  For more information, visit www.amirapharm.com.


'/>"/>
SOURCE Amira Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Amira Announces Second DP2 Antagonist Patent Grant in the United Kingdom
2. Anti-Fibrotic Data from Amira Pharmaceuticals LPA1 Receptor Antagonist Program Published in the British Journal of Pharmacology
3. Amira Pharmaceuticals Announces Efficacy of LPA1 Antagonist in a Preclinical Model of Scleroderma
4. Amira Pharmaceuticals Announces Initial Positive Phase 1 Clinical Data for AM461, A Back-Up to Amiras Lead DP2 Antagonist, AM211
5. Amira Pharmaceuticals Submits IND for Second DP2 Antagonist, AM461
6. Hanger Orthopedic Group, Inc. Announces Second Quarter 2010 Earnings Release Conference Call
7. K-V Pharmaceutical Announces Resubmission to New Drug Application for Gestiva™
8. Rcadia Announces Five COR Analyzer® Studies to be Presented at SCCT Annual Scientific Meeting
9. Medical Alarm Concepts™ Announces Roll-Out of the MediPendant™ at Albertsons
10. Biovista Announces the Appointment of Clifford H. Farrah to its Advisory Board
11. Telik Announces Publication of Review Focused on the Inhibition of the Enzyme GSTP1-1 as a Target for New Cancer Treatments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... -- Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today provided an ... Puerto Rico , where the company ... Following a comprehensive onsite assessment, ... damage, temporary loss of power and minimal water damage ... operations have resumed, and the company expects to return ...
(Date:10/10/2017)... --  West Pharmaceutical Services, Inc. (NYSE: WST), a ... today shared the results of a study highlighting the ... administration of polio vaccines. The study results were presented ... by Dr. Ondrej Mach , Clinical Trials and ... and recently published in the journal Vaccine. i ...
(Date:10/5/2017)...  In response to the nationwide opioid epidemic, ... (AAOMS) released prescribing recommendations that urge ibuprofen – ... a first-line therapy to manage a patient,s acute ... Recognizing the value and importance of the ... Acute and Postoperative Pain Management" stresses that practitioners ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... ... The Visiting Nurse Association (VNA) of Somerset Hills is proud to host ... items from across the nation, this holiday-themed event will raise funds and awareness for ... The boutique will be open Saturday, November 4 (10:00 a.m. – 5:00 p.m.) ...
(Date:10/13/2017)... ... , ... Talented host, actor Rob Lowe, is introducing a ... episode of "Success Files," which is an award-winning educational program broadcasted on PBS ... in-depth with passion and integrity. , Sciatica occurs when the sciatic nerve in ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... healthcare compliance program management, will showcase a range of technology and learning solutions ... Living (NCAL) Convention and Expo to be held October 14–18, 2017 at the ...
(Date:10/12/2017)... ... October 12, 2017 , ... IsoComforter, Inc. ( https://isocomforter.com ... introduction of an innovative new design of the shoulder pad. The shoulder pad ... comfort while controlling your pain while using cold therapy. By utilizing ice and water ...
(Date:10/12/2017)... , ... October 12, 2017 , ... ... Hair Restoration, has recently contributed a medical article to the newly revamped ... Dr. Mohebi’s article spotlights the hair transplant procedure known as Follicular Unit ...
Breaking Medicine News(10 mins):